Search

To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors.Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]).Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.1% (95% confidence interval: 68.0-73.9) at year 1% and 37.7% (95% CI: 33.3-42.1) at year 7 and at year 8. Retention was higher when golimumab was used as the first biological drug (81.7% at year 1, 49.9% at year 7, p 0.001). In Cox regression analysis, factors associated with golimumab retention included use as first-line therapy (hazard ratio [HR] for discontinuation 1.52 for second- and 1.79 for third/later-line vs. first-line), use in axial SpA or PsA rather than RA (HR for axial SpA vs. RA 0.59, for PsA vs. Rheumatoid arthritis 0.67), and treatment with concomitant methotrexate (HR 0.67). Factors associated with golimumab discontinuation were corticosteroid use (HR 1.46) and disease activity above median (HR 1.29) at golimumab initiation.Based on this retrospective analysis of the BIOBADASER registry, nearly two-fifths (37.7%) of adult rheumatology patients initiating golimumab will remain on treatment for 8 years, with a higher probability of retention in axial SpA or PsA indications and when golimumab is used as first biologic.

BackgroundSecukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA.Patients and methodsRetrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and ≥ third) for up to 24 months.Results221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a ≥ hird-line in 28%. The percentage of patients achieving low disease activity (BASDAIp = 0.05).ConclusionSecukinumab improved disease activity in axSpA patients, especially in naive, and second-line patients, which was accompanied by high persistence rates up to 24 months.

To analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life.A six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively.Levels of fatigue, moderate and severe insomnia significantly reduced after 6 months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P = .006). Data on pain and discomfort also show significant improvement after the treatment.Patients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6 months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being.

Objective To analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life. Methods A six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively. Results Levels of fatigue, moderate and severe insomnia significantly reduced after 6 months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P = .006). Data on pain and discomfort also show significant improvement after the treatment. Conclusions Patients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6 months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being.

Resumen Introduccion Los estudios de opinion sobre la percepcion del reumatologo de la practica asistencial en osteoporosis (OP) pueden ayudar a identificar areas de mejora en la gestion de esta patologia. Objetivo Conocer y analizar el enfoque organizativo que adoptan los reumatologos espanoles ante la OP para definir prioridades estrategicas y establecer unos estandares de calidad. Material y metodo Un grupo de expertos diseno una encuesta sobre creencias y conductas en OP en la practica del reumatologo. La encuesta se remitio a los socios de la Sociedad Espanola de Reumatologia (SER). Mediante ronda Delphi se consensuaron las prioridades estrategicas en OP. Resultados El grupo de expertos consensuo como prioridades estrategicas en OP: 1) La SER deberia impulsar la inclusion de la OP en el conjunto de prestaciones de todos los servicios de reumatologia, asi como ampliar la oferta formativa especifica para medicos y enfermeras; 2) Los servicios de reumatologia debieran fomentar el papel de la enfermera en OP, impulsar la implantacion y el seguimiento de indicadores de calidad e implantar protocolos de derivacion consensuados con atencion primaria ademas de impulsar su formacion en esta area; 3) La SER y los servicios de reumatologia deberian impulsar la implantacion de la consulta electronica y la consulta monografica o dedicada a OP asi como la participacion del reumatologo en unidades de fractura, Fracture Liaison Service. Conclusiones Las prioridades estrategicas en OP derivadas de la encuesta a los reumatologos espanoles ayudan a identificar las areas de mejora a nivel organizativo, estructural y de estandares de calidad en esta patologia.

Objective To describe a multicentre case series of new onset or worsening of psoriasis in patients treated with biological drugs. Material and methods Descriptive study. We reviewed the clinical history of patients with chronic inflammatory disease (CID) treated with biological drugs, who developed new onset or worsening of psoriasis during the follow-up period. Results Twenty-six cases of paradoxical psoriasis (PP) were recorded. Ninety-three percent of the patients were treated with anti-TNFα and adalimumab was responsible for 50% of the cases. Only 5 patients had a personal history of psoriasis. The biological drug was discontinued in 13 patients. Lesion recurrence was more frequent when another anti-TNFα was reintroduced. Conclusions The PP is a reversible adverse effect that can be observed in patients exposed to biological drugs, mainly anti-TNFα.

espanolObjetivo Describir una serie multicentrica de casos de induccion o empeoramiento de psoriasis en pacientes tratados con farmacos biologicos. Material y metodos Estudio descriptivo. Se reviso la historia clinica de pacientes con enfermedad inflamatoria cronica (EIC) en tratamiento con farmacos biologicos, y que presentaron durante el periodo de seguimiento, psoriasis de nueva aparicion o empeoramiento de la misma. Resultados Se registraron 26 casos de psoriasis paradojica (PP). El 93% de los pacientes estaban en tratamiento con un anti-TNFα, siendo el adalimumab el responsable del 50% de los casos. Solo 5 pacientes presentaban antecedentes personales de psoriasis. En 13 pacientes fue necesario retirar el farmaco biologico y la recidiva de las lesiones fue mas frecuente en los pacientes en los que se reintrodujo otro anti-TNFα. Conclusiones La PP es un efecto adverso reversible que se puede observar en pacientes expuestos a farmacos biologicos, principalmente a anti-TNFα. EnglishObjective To describe a multicentre case series of new onset or worsening of psoriasis in patients treated with biological drugs. Material and methods Descriptive study. We reviewed the clinical history of patients with chronic inflammatory disease (CID) treated with biological drugs, who developed new onset or worsening of psoriasis during the follow-up period. Results Twenty-six cases of paradoxical psoriasis (PP) were recorded. Ninety-three percent of the patients were treated with anti-TNFα and adalimumab was responsible for 50% of the cases. Only 5 patients had a personal history of psoriasis. The biological drug was discontinued in 13 patients. Lesion recurrence was more frequent when another anti-TNFα was reintroduced. Conclusions The PP is a reversible adverse effect that can be observed in patients exposed to biological drugs, mainly anti-TNFα.

Paciente con artritis reumatoide que tiene COVID-19 con debut de pericaditis recidivante, diagnóstico diferencial.

[Abstract] Objective. To determine and analyse the organisational approach adopted by Spanish rheumatologists to osteoporosis (OP) to define strategic priorities. Material and method. A group of experts designed a questionnaire on OP in the rheumatologist practice. The survey was sent to the Spanish Society of Rheumatology (SER) members. Through the Delphi round, strategic priorities were agreed upon in OP. Results. The priorities are: 1) The SER should promote the inclusion of OP in 100% of the services and expand the training offer; 2) Rheumatology services should promote the role of the nurse in OP, promote quality indicators and referral protocols agreed with primary care in addition to promoting their training in this area; 3) The SER and Rheumatology services should promote electronic consultation, OP monographic clinics and participation in Fracture Liaison Service units. Conclusions. Strategic priorities in OP help identify areas of improvement at organisational, structural and quality standards level in this pathology. [Resumen] Introducción. Los estudios de opinión sobre la percepción del reumatólogo de la práctica asistencial en osteoporosis (OP) pueden ayudar a identificar áreas de mejora en la gestión de esta patología. Objetivo. Conocer y analizar el enfoque organizativo que adoptan los reumatólogos españoles ante la OP para definir prioridades estratégicas y establecer unos estándares de calidad. Material y método. Un grupo de expertos diseñó una encuesta sobre creencias y conductas en OP en la práctica del reumatólogo. La encuesta se remitió a los socios de la Sociedad Española de Reumatología (SER). Mediante ronda Delphi se consensuaron las prioridades estratégicas en OP. Resultados. El grupo de expertos consensuó como prioridades estratégicas en OP: 1) La SER debería impulsar la inclusión de la OP en el conjunto de prestaciones de todos los servicios de reumatología, así como ampliar la oferta formativa específica para médicos y enfermeras; 2) Los servicios de reumatología debieran fomentar el papel de la enfermera en OP, impulsar la implantación y el seguimiento de indicadores de calidad e implantar protocolos de derivación consensuados con atención primaria además de impulsar su formación en este área; 3) La SER y los servicios de reumatología deberían impulsar la implantación de la consulta electrónica y la consulta monográfica o dedicada a OP así como la participación del reumatólogo en unidades de fractura Fracture Liaison Service (FLS). Conclusiones. Las prioridades estratégicas en OP derivadas de la encuesta a los reumatólogos españoles ayudan a identificar las áreas de mejora a nivel organizativo, estructural y de estándares de calidad en esta patología.

To determine and analyse the organisational approach adopted by Spanish rheumatologists to osteoporosis (OP) to define strategic priorities.A group of experts designed a questionnaire on OP in the rheumatologist practice. The survey was sent to the Spanish Society of Rheumatology (SER) members. Through the Delphi round, strategic priorities were agreed upon in OP.The priorities are: 1) The SER should promote the inclusion of OP in 100% of the services and expand the training offer; 2) Rheumatology services should promote the role of the nurse in OP, promote quality indicators and referral protocols agreed with primary care in addition to promoting their training in this area; 3) The SER and Rheumatology services should promote electronic consultation, OP monographic clinics and participation in Fracture Liaison Service units.Strategic priorities in OP help identify areas of improvement at organisational, structural and quality standards level in this pathology.

Background Survival, or persistence in treatment with a biological drug can be considered an indirect measure of efficacy, safety and tolerability Objectives We assessed the probability of persistence (survival) of treatment with golimumab in patients with rheumatic diseases and the factors associated to persistence with up to 6 years of follow-up. Methods BIOBADASER is the Spanish registry of biological drugs of the Spanish Society of Rheumatology and the Spanish Medicines Agency. A data-base analysis was done in December 2018 on all the patients aged 18 years or more who had initiated golimumab for one of the approved indications (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]). The probability of persistence was calculated with a Kaplan-Meier test. Factors related to persistence were analyzed with a Cox-regression model. Results 581 patients were included (165 [28.4%] RA, 249 [42.9%] axial SpA and 167 [28.7%] PsA), mean age 51 [12] years, 53% women). Median duration of disease at the onset of golimumab was 8.0 (3.0-14.7) years. Golimumab was prescribed as first biological drug in 37.9% of the patients, as second in 32.1% and as third or further in 30.0%. Concomitant medications at golimumab initiation included steroids (28.2%), methotrexate (MTX) (35.5%), sulphasalazine (7.2%) and leflunomide (13.9%). The probability of persistence of treatment with golimumab since treatment initiation was 74.3% at year 1 (95% CI 70.3 – 77.8), 63.5% at year 2 (59.0 – 67.6), 60.5% at year 3 (55.9 – 65.8), 54.5% (49.1 – 59.7) at year 4 and 5, and 52.1% (44.9 – 57.7) at year 6. Persistence was higher when golimumab was used as first biological agent (p log-rank Conclusion The probability of persistence (survival) on therapy with golimumab was high up to 6 years of follow-up and was higher in patients treated with golimumab as first biological drug or for PsA and SpA, and lower in those needing steroids, DMARDs different to MTX and in women. Acknowledgement This study was funded by Merck Sharp & Dohme of Spain. Disclosure of Interests Manuel Pombo: None declared, Carlos Sanchez-Piedra: None declared, Eduardo Cuende: None declared, Raquel Martin-Domenech: None declared, Javier del Pino: None declared, Cristina Campos Fernandez: None declared, Javier Manero: None declared, Blanca Garcia-Magallon: None declared, Fernando Sanchez-Alonso: None declared, Federico Diaz-Gonzalez Grant/research support from: MSD, Abbvie, Roche, Novartis, Consultant for: Lilly, Novartis, Pfizer, Amgen, Biogen, Celgene, Speakers bureau: MSD, Lilly, Janssen, BMS, Roche, Maria J. Arteaga Employee of: MSD, Luis Cea-Calvo Employee of: MSD, Juan J. Gomez-Reino: None declared

Background JAK inhibitors (JAKi) have been recently authorized in the European Union. JAKi long-term performance in the clinical practice setting still needs to be assessed. Drug survival reflects a drug’s effectiveness, safety, and tolerability; thus, it is an important measurement for real-world studies. Objectives To describe the pattern of use of JAKi in real-world dataset, and to analyze the drug survival as a group (tofacitinib+baricitinib). Methods Information was obtained from BIOBADASER III, an ongoing observational longitudinal multicenter cohort of patients with rheumatic diseases treated with biologic or targeted synthetic (b/ts) DMARDs in Spain. All subjects with current or previous JAKi use were included and followed until September 2018. Clinical characteristics of the patients were analyzed. Drug survival (overall, and for biologic-naive and biologic-experienced patients) was determined using Kaplan-Meier analysis. Results 149 patients, 75.2% women, were treated with JAKi, receiving a total of 152 cycles of treatment (50.7% tofacitinib, 49.3% baricitinib; 3 patients had both). The most frequent diagnosis was rheumatoid arthritis (RA, 92.6%), and there is a small number of off-label uses (6%), depicted at Table 1. Use on psoriatic arthritis is scarce (1.3%). Concomitant use of methotrexate (MTX) was registered in 68 patients (45.6%). Previous use of bDMARDs was high (n=124, 81.6%); drug survival rate for biologic-experienced patients was 81.7% and 78.7% at 6 and 12 months. None of the JAKi treatments in biologic-naive patients (n=18, 18.4%) were discontinued during follow-up. Pooled survival rate of JAKi was 85.0% and 82.5% at 6 and 12 months (Figure 1). Discontinuation was seen in 19 treatments (12.5%); the reasons were inefficacy (n=15, 9.9%) or adverse events (n=4, 2.6%). Conclusion The current use of JAKi in Spain is mainly in RA and as 2nd line after bDMARDs. The use of JAKi in psoriatic arthritis is still scarce and a small group of patients are treated off-label. Less than half use combination therapy with MTX. Overall survival of JAKi is superior to 80% at 12 months. A longer follow-up is needed to continue analyzing the survival of JAKi in a real-world context. Acknowledgement We thank all researchers from the BIOBADASER III group. Disclosure of Interests Valentina Emperiale: None declared, Carlos Sanchez-Piedra: None declared, Eduardo Cuende: None declared, Paloma Vela-Casasempere Grant/research support from: UCB, Abbvie, Pfizer, Roche, Bristol-Myer-Squibb (another research, not BIOBADASER related), Consultant for: UCB, Lilly, Pfizer, Roche, Bristol-Myer-Squibb, Speakers bureau: Roche, UCB, MSD, Pfizer, GSK, BMS, Lilly, Maria del Carmen Castro Villegas Paid instructor for: MSD, Abbvie, Pfizer, Janssen, Lilly, Roche, Sara Manrique Arija Speakers bureau: ABBvie, MSD, Janssen, Lillly, Roche, Pfyzer, Novartis., Cristina Campos Fernandez: None declared, Javier del Pino: None declared, Manuel Pombo: None declared, Fernando Sanchez-Alonso: None declared, Juan Jesus Gomez-Reino: None declared

Background The goal of this study was to validate the use of capillary blood in a real point-of-care (POC) setting for patients under infliximab treatment by using Promonitor Quick lateral flow (LF) tests. Results were compared to the Promonitor ELISA reference technique in serum samples used by centralised laboratories. Methods A prospective, observational study was designed to evaluate the performance of a rapid LF test (Promonitor Quick IFX, Progenika, Spain). 160 infliximab treated rheumatology consecutive patients (400 samples) were recruited in two hospitals in Galicia, Spain. Prior to the infusion, a finger prick sample was obtained and analysed. Anti-infliximab antibodies were also determined with Promonitor Quick ANTI-IFX1-4. Results were read with the automated portable PQreader instrument. Additionally, a serum sample was collected for subsequent comparative analysis with either LF or ELISA tests. Qualitative (positive (PPA) and negative (NPA) agreements) and quantitative (Pearson correlation and bias) performance of the LF test was compared to ELISA, as well as between different specimens following CLSI EP09-A3. Results Overall agreement between Promonitor Quick IFX finger prick and ELISA test was 91% (88% PPA; 100% NPA). The quantitative comparison showed a good correlation (Pearson correlation coefficient: 0.85 and observed bias: 25%) (Table 1). Similar results were also observed when serum was used with either the LF or the ELISA tests (98% overall agreement, 0.91 correlation coefficient; 6% bias) (Table 1). Overall agreements for visual and automated (PQreader) interpretations with Promonitor Quick ANTI-IFX were 99% and 100% for finger prick and serum specimens, respectively (Table 2). Conclusion Promonitor Quick can be used to reliably quantify infliximab in capillary blood samples and results are comparable to those obtained with the reference ELISA technique. The use of the rapid POC test with finger prick will allow clinicians to monitor their patients in a fully decentralized mode to aid in the decision making process. PQreader is a sensitive portable equipment to report drug as well as antibody levels in the patient samples. References

Resumen La enfermedad de Behcet (EB) es una vasculitis sistemica, y afecta con mayor agresividad a varones jovenes. Sus manifestaciones mas frecuentes son las aftas orogenitales, la uveitis y las lesiones cutaneas. Analizamos 6 pacientes con EB, que recibieron adalimumab para controlar la enfermedad. Todos habian recibido terapia inmunosupresora, ademas 2 de ellos recibieron infliximab. Observamos una buena respuesta clinica al farmaco. Actualmente, con un seguimiento medio de 26,8 meses, los pacientes siguen en tratamiento con adalimumab, con buen control clinico y sin que se hayan detectado efectos adversos relacionados con el anti-TNF.

Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab.

Background It has been described a higher prevalence of metabolic syndrome (MetS) in patients with spondyloarthitis (SpA), particularly in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Objectives To describe the prevalence of MetS in SpA patients identifying associated factors and to make a comparison between patients with AS and PsA. Methods Observational and retrospective study of 410 SpA patients (188 AS according to modified New York criteria and 222 PsA according to CASPAR criteria) belonging to our follow-up cohort (2004-2014) of northwest of Spain. Demographic, clinical and laboratory data were collected corresponding to baseline visit. MetS was defined according to Adult Treatment Panel III (ATPIII) criteria. Qualitative variables were analyzed using Chi-square/Fisher test and for quantitative variables we used Student t/U Mann Whitney test. Statistical analysis was performed by SPSS 21.0 program. It was considered p Results Of the 410 patients, 68.3%, 280 were men (78% in AS and 60% in PsA, p Conclusions We demonstrate an elevated prevalence of MetS in SpA patients; that is higher in PsA than in AS patients. These results highlight the importance of detection and early treatment of cardiovascular risk factors in SpA patients. Disclosure of Interest None declared

Background Carotid artery ultrasound (US) is a useful tool to asses subclinical atheromatosis. An increased intima-media thickness (IMT) has been described in patients with Spondiloartritis (SpA), mainly in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Objectives To evaluate subclinical atheromatosis in patients with SpA identifying associated risk factors and to design a scoring system that allow us to detect patients with increased risk of developing subclinical atheromatosis. Methods Observational and cross-sectional study of 100 SpA patients, randomly selected from their follow-up visit (2012-14). Demographic, clinical and laboratory data were collected. IMT was measured in mm with a Kotron Agile probe.IMT >0.9mm or visualization of atheroma plaque was considered positive US (US+). SPSS v21.0 was used for statistical analysis, considering p Results A total of 100 patients (59 APs and 41 AS) were included, mean age of 47 years (±13); 61% were men. Mean IMT was 0.64mm (±0.16). Eight patients had a GIM >0.9mm and 11 patients had atheroma plaques. A total of 18 patients had US+. Variables associated with increased IMT and US+ are described in table 1. In the multivariate analysis US+ was associated with elevated serum levels of C-reactive protein, increased waist circumference, increased systolic blood pressure and age >60 years. We design AROSpA (Age, Reactive C-protein, central Obesity, Sex, Systolic pressure, Score in SpA) risk score system based on these results. Cut-off points were chosen according to clinical established criteria and optimal likehood ratios in significant COR curve analysis. One point was assigned to each of the following items: Age >60 years, C-reactive protein >1mg/dL, waist circumference >102/88cms (men/women), men sex gender, systolic blood pressure >130 mmHg, and SCORE risk >2%. In the COR curve analysis, AROSpA >4 predicted US+ (sensitivity 100%, specifity 86%, positive likehood ratio (LH+) of 7.1; with an area under the curve (AUC) of 0.899, CI 95% 0.827-0.971, p Conclusions US+ was described in 18% SpA patients and it was associated with increased levels of CRP, waist circumference, blood pressure, age and risk in SCORE chart. AROSpA seems to be a simple, cheap and easy scoring system tool that would allow us to identify patients in whom carotid US should be performed to screening subclinical atherosclerosis with high sensitivity and specificity. These results should be validated in a prospective well-designed study, which we are currently underway. Disclosure of Interest None declared

A 68-year-old male patient was admitted to the internal medicine department due to a 10 kg weight loss in a 6 month period. This was accompanied by night sweating and red spots on the arms and legs which were painful, lingered on for several days and disappeared leaving a hyperpigmented lesion. The patient had also been constipated for a month before his admission. He had no history of contact with animals, recent travel or infectious processes. He was in an adequate general state, had mild fever and no palpable peripheral lymphadenopathy. His heart and lungs were normal. The abdomen was normal. He had residual hyperpigmented spots on the extremities. Laboratory analysis revealed an ESR of 120 mm/h, CRP of 14.90 mg/dL, and Hb of 9.6 g/dL with a MCV of 90.9. Tumor markers (CEA, CA 15,3, CA 19,9, PSA AFP, B2 microglobulin), thyroid function tests, rheumatoid factor, and autoantibodies (ANA, ENA and ANCA)1 were negative. Serology (HBV, HCV, Lyme, Coxyella, Rickettsia, CMV, toxoplasma, and parvovirus) as well as Mantoux A R T I C L E I N F O

Background Psoriatic arthritis (PsA) is a disease developed in 10-20% of psoriasis patients. HLA–Cw*06 has been identified as the major genetic determinant of susceptibility to psoriasis. Objectives To estimate the prevalence of HLA-Cw6 and Cw7 in healthy population, patients with psoriasis without joint disease and patients with PsA and to analyze the influence of both alleles in the characteristics of PsA. Methods Genotyping of HLA-Cw * 06 and * 07 was performed on DNA samples of 390 Caucasian subjects by PCR-SSP (Sequence specific primer). The allele frequencies of HLA-Cw * 06 and * 07 were determined in patients with psoriasis (n = 117), PsA (n = 172), and compared with those of healthy controls (n = 101), and we calculated the odds ratio and confidence interval of 95% (OR, 95% CI). We determined the association of alleles with clinical-radiological forms of PsA (peripheral and axial / mixed). We used the chi-square test, Fisher’s exact test and t Student. We consider to be significant at p Results The frequencies of HLA-Cw * 06 were higher in type 1 psoriasis (OR 7.1, 95% CI 1.8-27.9, P ); although PsA patients with type I psoriasis had been diagnosed before patients with type II psoriasis (40.0 years (12.2) vs 57.6 (9.7), p Conclusions HLA-Cw * 06 and its main subtype * 0602, are more prevalent in our patients with cutaneous psoriasis and psoriatic arthritis compared with healthy controls, and are more frequent in patients with a diagnosis of an earlier age. There was no influence on other features analyzed in PsA patients We found no difference in HLA-Cw * 07. Acknowledgements The authors thank Jose Luis Fernandez-Sueiro for him hard work and dedication. Rest in peace. Disclosure of Interest None Declared